These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 8956123)

  • 21. Effects of cardiac resynchronization therapy on disease progression in patients with congestive heart failure.
    Bonanno C; Ometto R; Pasinato S; Finocchi G; La Vecchia L; Fontanelli A
    Ital Heart J; 2004 May; 5(5):364-70. PubMed ID: 15185900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Influence of pacing site on myocardial transmural dispersion of repolarization in intact normal and dilated cardiomyopathy dogs].
    Bai R; Pu J; Liu N; Lu JG; Zhou Q; Ruan YF; Niu HY; Wang L
    Sheng Li Xue Bao; 2003 Dec; 55(6):722-30. PubMed ID: 14695492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE; McKinnie JJ; Greenberg SS; Giles TD
    Prog Cardiovasc Dis; 1999; 41(4):265-300. PubMed ID: 10362349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial.
    Das SR; Drazner MH; Yancy CW; Stevenson LW; Gersh BJ; Dries DL
    Am Heart J; 2004 Nov; 148(5):883-8. PubMed ID: 15523322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Head-to-head comparison of BNP and IL-6 as markers of clinical and experimental heart failure: Superiority of BNP.
    Birner CM; Ulucan C; Fredersdorf S; Rihm M; Löwel H; Stritzke J; Schunkert H; Hengstenberg C; Holmer S; Riegger G; Luchner A
    Cytokine; 2007 Nov; 40(2):89-97. PubMed ID: 17920926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction.
    Hayashidani S; Tsutsui H; Shiomi T; Ikeuchi M; Matsusaka H; Suematsu N; Wen J; Egashira K; Takeshita A
    Circulation; 2003 Oct; 108(17):2134-40. PubMed ID: 14517168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure.
    Khattar RS
    Minerva Cardioangiol; 2003 Apr; 51(2):143-54. PubMed ID: 12783070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
    Gradman AH; Alfayoumi F
    Prog Cardiovasc Dis; 2006; 48(5):326-41. PubMed ID: 16627048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diabetes mellitus, left ventricular dysfunction and congestive heart failure].
    Tarantini L; Di Lenarda A; Velussi M; Faggiano P; Comaschi M; Faglia E; Maggioni AP
    Ital Heart J Suppl; 2004 Aug; 5(8):605-15. PubMed ID: 15554015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical management of congestive heart failure.
    Arai AE; Greenberg BH
    West J Med; 1990 Oct; 153(4):406-14. PubMed ID: 2244376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathophysiology and therapy of heart failure, new insights and developments. Part I.
    Remme WJ
    Neth J Med; 1992 Oct; 41(3-4):171-82. PubMed ID: 1470289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathophysiology of cardiomyopathies: Part I. Animal models and humans.
    Davidoff AJ; Gwathmey JK
    Curr Opin Cardiol; 1994 May; 9(3):357-68. PubMed ID: 8049594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primate models for cardiovascular drug research and development.
    Shen YT
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1025-9. PubMed ID: 20730697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Epidemiology and pathophysiology of heart failure].
    Meyer BJ; Amann FW
    Schweiz Rundsch Med Prax; 1992 May; 81(21):679-86. PubMed ID: 1534920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hemodynamic characteristics of chronic congestive heart failure model in awake Beagle dogs].
    He X; Liu Y; Zhang Y; Zhang R; Yang B
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jun; 34(6):487-91. PubMed ID: 19587429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early changes in contractility indices and fibrosis in two minimally invasive congestive heart failure models.
    de Souza Vilarinho KA; Petrucci O; Baker RS; Vassallo J; Schenka AA; Duffy JY; de Oliveira PP; Vieira RW
    Eur J Cardiothorac Surg; 2010 Feb; 37(2):368-75. PubMed ID: 19945295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathophysiology of cardiomyopathies: Part II. Drug-induced and other interventions.
    Gwathmey JK; Davidoff AJ
    Curr Opin Cardiol; 1994 May; 9(3):369-78. PubMed ID: 8049595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New therapeutic strategies in the management of congestive heart failure.
    Brunelli C; Ghigliotti G; Martini U; Caponnetto S
    Eur Heart J; 1991 Dec; 12 Suppl G():53-7. PubMed ID: 1806381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular changes during maturation and ageing in male and female spontaneously hypertensive rats.
    Chan V; Fenning A; Levick SP; Loch D; Chunduri P; Iyer A; Teo YL; Hoey A; Wilson K; Burstow D; Brown L
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):469-78. PubMed ID: 21283019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new model of congestive heart failure in anesthetized dogs.
    Chong LJ; Smith TD; Povzhitkov MM
    Proc West Pharmacol Soc; 1985; 28():81-5. PubMed ID: 4070267
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.